In the News | Friends of Cancer Research

You are here

In the News

Convenience Store Decisions - Senate Committee Advances FDA Nomination

A Senate committee has advanced the nomination of Dr. Stephen Hahn as the Food and Drug Administration (FDA) commissioner, with a vote of 18 to 5 in favor.

 

Hahn, chief medical executive at the University of Texas M.D. Anderson Cancer Center, was nominated by President Trump last month to replace Dr. Scott Gottlieb, who left in April.

 

Hahn must be confirmed by the Senate still, but a vote has yet to be scheduled.

 

PMLive - Senate panel confirms Stephen Hahn as next FDA commissioner

MD Anderson exec Stephen Hahn (pictured above) breezed through a senate committee vote yesterday, advancing him forward for the formidable FDA commissioner title.

 

Hahn was approved for FDA commissioner in an 18-5 vote, after he was put forward for the job by President Donald Trump.

 

The Senate Committee on Health, Education, Labor and Pensions voted in favour of advancing Hahn’s nomination to the full Senate.

 

Pink Sheet - Hahn's Nomination Heads To Full Senate Following Bipartisan Endorsement From HELP Committee

Executive Summary

The Senate HELP Committee votes 18-5 to send Stephen Hahn's nomination to head the US FDA to the full chamber, although a few senators raised concerns over Hahn's responses to questions about e-cigarettes during his confirmation hearing.


Stephen Hahn's nomination to serve as commissioner of the US Food and Drug Administration advanced to the full Senate following a relatively painless 18-5 vote from the Health, Education, Labor and Pensions Committee on 3 December.

S&P Global Market Intelligence - Health panel clears way for Senate consideration of US FDA candidate Hahn

The Senate Health, Education, Labor and Pensions Committee voted 18 to 5 to advance the nomination of cancer doctor and radiation oncologist Stephen Hahn to lead the U.S. Food and Drug Administration.

 

Hahn is the chief medical executive at the University of Texas MD Anderson Cancer Center in Houston.

 

He has no regulatory or industry background. His only government experience was serving in the U.S. Public Health Service at the U.S. National Cancer Institute from 1989 to 1995.

 

Endpoints News - Senate committee backs Stephen Hahn as the next FDA commissioner

A Senate committee handily voted in favor of confirming MD Anderson’s Stephen Hahn as the next official FDA commissioner, succeeding the inimitable Scott Gottlieb. And he was whisked through the 18-5 vote on the back of some tardy praise from a host of healthcare groups — including quite a few that initially supported acting commissioner Ned Sharpless for the job.

 

In the end, the outcome of the vote Tuesday morning wasn’t really in question, especially considering the lukewarm opposition he faced during his job interview during the Senate hearing on the nomination.

Regulatory Focus - Senate Committee Advances Nomination of Hahn as FDA Commissioner

The Senate Health, Education, Labor and Pensions (HELP) Committee on Tuesday voted 18 to 5 to advance the nomination of Stephen Hahn to be the next US Food and Drug Administration (FDA) commissioner.

 

HELP Committee Chairman Lamar Alexander (R-TN) pledged his support for Hahn and said he hopes the full Senate will vote on Hahn’s nomination by the end of the month.

 

The New York Times - F.D.A. Nominee Clears Senate Panel

A Senate committee on Tuesday advanced the nomination of Dr. Stephen Hahn, a noted oncologist and cancer researcher, to lead the Food and Drug Administration.

 

Dr. Hahn, chief medical executive at the University of Texas M.D. Anderson Cancer Center, was nominated by President Trump last month to replace Dr. Scott Gottlieb, who left the job in April.

 

Inside Health Policy - Over 40 Health Orgs Voice Support For Hahn Ahead Of Committee Vote

More than 40 health and advocacy organizations penned a letter to lawmakers expressing support for Stephen Hahn to be the new FDA commissioner and calling for a swift confirmation. The groups sent the letter to Senate leaders Monday (Dec. 2), a day ahead of the Senate health committee’s scheduled vote to advance Hahn’s nomination to the full Senate.

 

Pink Sheet - Real-World Database Studies: Prepare For A Long Journey, IQVIA Advises

Executive Summary

Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper shows.

 

“Real-world database studies are a long journey,” IQVIA Real World Solutions UK associate principal Paola Nasuti observed in an interview with the Pink Sheet.

 

Pages